Jun. 23, 2014
Jiangsu-based Hengrui Medicine announced that its cancer drug Oxaliplatin received approval for marketing and sale in the US market. The drug is a generic treatment for colon and rectum cancer. Hengrui, whose major focus is chemotherapies, has annual revenues of $1 billion. Hengrui already markets Oxaliplatin in China and Europe.
Concurrently, Hengrui announced that Apatinib, its oral treatment for metastatic gastric cancer, successfully completed a Phase III trial in China. Data from the trial was presented at the recent ASCO conference in Chicago. Hengrui has filed with the CFDA for marketing approval of Apatinib in China.